Evolving Concepts in ADPKD
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited kidney disease and the 4th leading cause of patients progressing to end-stage kidney disease (ESKD) requiring either dialysis or a kidney transplant. Despite the significant morbidity and mortality associated with ADPKD, most nephrologists are unsuspecting about its disease pathophysiology, contemporary diagnostic methods, and contemporary prognostic methodsâincluding tools for identifying those patients at risk for rapid progression of disease. This has led to suboptimal clinical outcomes for patients suffering from ADPKD.
During this informative session, Dr. Frederic Farid Rahbari-Oskoui, will discuss the clinical presentations of ADPKD, contemporary diagnostic and prognostic tools, PKD1 and PKD2 genotype-phenotype correlations, with illustrative cases from his own practice. Dr. Michal Mrug will explore the evolution of the concept of total kidney volume (TKV) as reflective of ADPKD disease status, and its validation as a prognostic tool for identifying patients at low, intermediate, and high risk for rapid disease progression to kidney failure. Dr. Mrug will also speak about FDA and EMA's qualification of TKV as a prognostic enrichment biomarker for selecting patients at high risk for a progressive decline in kidney function for inclusion in clinical trials.
MAT-US-2019183v1.0
Expiration Date: 3/31/2021
Dr. Mrug co-founded and directs the UAB Polycystic Kidney Disease (PKD) Clinic and oversees clinical PKD research activities at UAB since 2009. This includes the CRISP study, an NIH-funded collaborative effort between Emory University, University of Kansas, Mayo Clinic, UAB and University of Pittsburgh that has led to many seminal discoveries. His clinical research interests are centered on the development of statistical models for prediction of the decline in the kidney function in patients with autosomal dominant polycystic kidney disease over time and better identification of those patients that may benefit most from therapeutic interventions. Dr. Mrug's basic research is focused on the identification of molecular pathways that modulate progression of renal cystic diseases, especially those related to inflammation. He also directs the Therapeutics Development and Screening Resource, one of four cores within the UAB Childhood Cystic Kidney Disease Core Center.
Dr. Rahbari-Oskoui is the director of Cystic Kidney Diseases Clinic at Emory University and a nephrologist practicing at Emory University Hospital, the Emory Clinic, and the Grady Memorial Hospital. He has co-authored more than 60 original manuscripts, review articles, textbook chapters and is a regular author for UpToDate on cystic diseases of the kidneys and polycystic kidney disease. He specializes in cystic diseases of the kidneys, inherited diseases of the kidneys, hypertension, ambulatory blood-pressure monitoring, and imaging in kidney diseases and he is involved in caring for patients with kidney diseases as well as conducting research in those fields. Dr. Rahbari-Oskoui is also an investigator in several landmark trials and observational cohorts.
